IL-15-overexpressing mice in an allergen-induced murine model of asthma. We assessed eosinophil numbers by using anti-major basic protein immunostaining, goblet cell hyperplasia by using periodic acid-Schiff staining, and cytokine and chemokine levels by performing quantitative PCR and ELISA. Results: We made a novel observation that IL-15 deficiency promotes baseline airway resistance in naive mice. Moreover, rIL-15 delivery to the lung downregulates expression of proinflammatory cytokines and improves allergen-induced AHR, airway resistance, and compliance. These observations were further validated in doxycycline-inducible CC10-IL-15 bitransgenic mice. Doxycycline-exposed, Aspergillus species extract-challenged CC10-IL-15 bitransgenic mice exhibited significantly reduced levels of proinflammatory cytokines (IL-4, IL-5, and IL-13) and decreased goblet cell hyperplasia. Airway obstruction, including AHR and airway resistance, was diminished in allergen-challenged doxycycline-exposed compared with non-doxycycline-exposed CC10-IL-15 bitransgenic mice. Mechanistically, we observed that IL-15-mediated protection of airway obstruction is associated with induced IFN-g-and IL-10-producing regulatory CD4
1 CD25
1
The occurrence of asthma is increasing throughout the world, including the United States. Nearly 25 million persons, 8.6% of adults and 14% of children, have this chronic inflammatory pulmonary disorder, which is also responsible for more than 5000 deaths per year (http://www.aafa.org). 1, 2 Hence there is a great need to continue with innovative fundamental studies to uncover new possibilities for therapeutic interventions that will prevent or treat airway obstruction. Currently, antiinflammatory corticosteroid inhalers and other medications are available to treat airway inflammation and obstruction. 3, 4 These treatments bring about a significant reduction in inflammation but do not restrict or reverse the progression of the bronchial airway obstruction and fibrosis.
Airway obstruction is not a disease per se but rather represents a physiologic manifestation of airway narrowing as a consequence of inflammation and scarring. Airway reactivity is an important component of the diagnostic criteria for examining bronchial asthma using a variety of stimuli, including methacholine (MCh), histamine, hypertonic saline, distilled water, exercise, or eucapnic hyperventilation. [5] [6] [7] Asthma is a chronic inflammatory airway disease characterized by activation of inflammatory cells and mediators, variable obstruction, hyperresponsiveness, and airway remodeling. [8] [9] [10] Substantial research in the field of bronchial asthma within the last 2 decades was aimed at identifying inflammatory cell products responsible for the pathogenesis of bronchial asthma, including airway hyperresponsiveness (AHR) and airway resistance (resistance). 11, 12 Measurements of AHR have traditionally been used to identify patients with intermittent obstruction. 12 Presently, it is believed that AHR can result from the coordination of several mechanisms, some or all of which might be operative in individual asthmatic patients. In asthmatic patients there is a relationship between the inflammatory state of the airways and the severity of hyperresponsiveness.
Clinical and experimental investigations have demonstrated a strong correlation between the presence of CD4
1 T H 2 and T H 3 lymphocytes and disease severity, suggesting an integral role for these cells in the pathophysiology of asthma. 13, 14 Studies have identified increased production of IgE, mucus hypersecretion, and eosinophilic inflammation, which lead to obstructive lung function abnormalities and airway fibrosis. [15] [16] [17] [18] [19] [20] T H 2 cells are thought to induce asthma through secretion of an array of cytokines (IL-4, IL-5, IL-6, IL-9, and IL-13) that activate inflammatory and resident effector pathways in the lung both directly and indirectly. 21, 22 In particular, investigations have identified IL-13 as a potential key regulator of the pathogenic mechanism or mechanisms underlying allergic disease. IL-13 is expressed at exaggerated levels in patients with atopic and nonatopic asthma. 23, 24 IL-15 is a cytokine implicated in innate and acquired antiviral immunity, and its association with pediatric asthma has been reported. 25 Another article indicated that IL-15 deficiency exacerbates asthma in children. 26 What is more, higher levels of IL-15 were found in steroid-treated asthmatic patients. 25 However, to date, the role of IL-15 in asthma pathogenesis has not yet been explored. Importantly, IL-15 is a requisite for the generation or maintenance of specific hematopoietic lineages, and IL-15 receptors are expressed on dendritic cells, monocytes, natural killer (NK) cells, and a number of T-cell subtypes, including NKT, naive, and memory CD8
1 T cells and gd T cells.
27,28
Therefore, we focused our studies on understanding the modulatory effects of IL-15 on allergen-induced airway obstruction, including airway AHR, resistance, and compliance. Accordingly, we first examined whether endogenous IL-15 deficiency exacerbates baseline airway resistance and whether rescue use of IL-15 in Il15 gene-deficient (Il15
) mice would improve airway resistance and compliance. In addition, we provide evidence that both pharmacologic delivery of rIL-15 to the lung and lung-targeted transgenic IL-15 overexpression protects mice against allergen-induced initiation of AHR, resistance, and compliance. Taken together, our findings show that IL-15 is critical for the development of asthma and has the potential to serve as a therapeutic agent for the treatment of airway obstruction in asthmatic patients.
METHODS Mice
rtTA-CC10-IL-15 bitransgenic mice were generated and details were described in the results, and backcrossed onto the BALB/c background in our laboratory. Il15 2/2 BALB/c mice were kindly donated by Dr Fred D.
Finkelman (Cincinnati Children's Hospital Medical Centre, Cincinnati, Ohio). Specific pathogen-free wild-type BALB/c mice (8-10 weeks old) were obtained from the Jackson Laboratory (Bar Harbor, Me). The Tulane Institutional Animal Care and Use Committee approved the animal protocols that were used in accordance with National Institute of Health guidelines.
Induction of airway allergic inflammation
A murine model of allergic lung disease was used with 3 different allergens, house dust mite, cockroach, and Aspergillus species extracts, per the methods described previously. [29] [30] [31] In brief, mice were lightly anesthetized with isoflurane inhalation (Methoxy-fluorane; Pittman-Moore, Mundelein, Ill), and 100 mg (50 mL) of Aspergillus fumigatus, cockroach, or house dust mite extracts (Greer Laboratories, Lenoir, NC) or 50 mL of normal saline alone was applied to the nares with a micropipette 3 times per week for 3 weeks to induce lung inflammation.
rIL-15 or ALT-803 pretreatment rIL-15 (10 mg/50 mL; PeproTech, Rocky Hill, NJ), ALT-803 (5 mg/50 mL; Alter biosciences, Miramar, Fla), or saline (50 mL) was used to pretreat allergen-challenged mice through the intranasal route 2 times a week for 3 weeks during the experimental regimen, as described above. Mice were sacrificed between 18 and 20 hours after the last intranasal challenge.
Anti-IL-15 neutralization
Anti-mouse rabbit polyclonal IL-15 neutralization antibody (1 mg/mL, PeproTech) or rabbit IgG (control) was administered intraperitoneally to mice 30 minutes before challenge with Aspergillus species extract, according to the protocol described above.
Measurement of AHR
AHR to methacholine was assessed in conscious unrestrained mice by using barometric plethysmography with the apparatus and software supplied by Buxco Electronics (Troy, NY). This system yields a dimensionless parameter known as enhanced pause (Penh), reflecting changes in the waveform of the pressure signal from the plethysmography chamber combined with a timing comparison of early and late expiration. of methacholine (MCh) were measured, and comparison data are presented. C, Protocol followed for IL-15 level modulation and induction of asthma in mice. i.n., Intranasal. D and E, Anti-IL-15-neutralized mice show exuberated resistance and compliance at baseline and with allergen-induced asthma compared with nonneutralized saline-and Aspergillus species-challenged mice. Data are expressed as mean 6 SD (n 5 6 mice per group in each group). *P < .04 and **P < .001.
Measurement was performed, as previously described. 32, 33 Briefly, mice were placed in the plethysmography chamber and exposed to an aerosol of water (baseline readings) and then cumulative concentrations of methacholine (Sigma-Aldrich, St Louis, Mo) ranging from 3.125 to 25 mg/mL. The aerosol was generated by using an ultrasonic nebulizer and drawn through the chamber for 2 minutes. The inlet was then closed, and Penh readings taken over 3 minutes were averaged. Values were reported as the increase over baseline values.
Measurement of airway resistance and compliance
The trachea was surgically exposed in anesthetized mice, and a cannula was inserted and tied with a suture to prevent air leakage. 34 Mice were placed in the Finepoint RC system chamber (Data Sciences International, St Paul, Minn) and connected to a ventilator. Mechanical ventilation was started with the appropriate respiratory rate and tidal/stroke volume. After 2 baseline measurements lasting 3 minutes, mice were exposed to PBS or methacholine (3.125-50 mg/mL), and their airway resistance and compliance were measured according to the manufacturer's defined protocol.
Eosinophil analysis
Paraffin-embedded lung tissue sections (5 mm) were immunostained with antiserum against mouse eosinophil major basic protein (anti-MBP), as described previously. 33, [35] [36] [37] In brief, endogenous peroxidase in the tissues was quenched with 0.3% hydrogen peroxide in methanol, followed by nonspecific protein blocking with 3% normal goat serum. Tissue sections were then incubated with rat anti-MBP antibody (1:6000 dilution) overnight at 48C (kindly provided by Drs James and Nancy Lee, Mayo Clinic, Scottsdale, Ariz), followed by a 1:250 dilution of biotinylated goat anti-rat IgG secondary antibody and avidin-peroxidase complex (Vector Laboratories, Burlingame, Calif) for 30 minutes each. Slides were further developed with nickel diaminobenzidine-cobalt chloride solution to form a black precipitate and counterstained with nuclear fast red. Negative controls included replacing the primary antibody with normal goat serum to control for endogenous biotin and peroxidase activity.
Analysis of goblet cell hyperplasia
Lung tissue samples were fixed with 10% paraformaldehyde in PBS (pH 7.4), embedded in paraffin, cut into 5-mm sections, and fixed to positively (Fig 2, A) , IL-5 (Fig 2, B) , IL-13 (Fig 2, C) , IL-10 (Fig 2, D) , IgE (Fig 2, E) , and IFN-g (Fig 2, F) levels in control and rIL-15-treated saline-or Aspergillus species-challenged mice are shown. G and H, BALF eosinophil (Fig 2, G) and PAS 1 goblet cell numbers (Fig 2, H ) in control and rIL-15-treated saline-or Aspergillus species-challenged mice. I-K, AHR (Fig 2, I ), airway resistance (RI; Fig 2, J) , and compliance (Cydn; Fig 2, K) in response to methacholine (MCh) measured in saline-challenged, rIL-15-pretreated salinechallenged, Aspergillus species-challenged alone, and rIL-15-pretreated Aspergillus species-challenged groups of mice. Data are expressed as mean 6 SD (n 5 12 mice per group). *P < .05, **P < .001, and ***P < .0001.
charged slides. Periodic acid-Schiff (PAS) reaction staining (Poly Scientific R&D, Bay Shore, NY) was performed on the tissue sections, according to the manufacturer's recommendations. Quantification of mucus-stained cells was assessed with morphometric analysis by using the MetaMorph Imaging System (Universal Imaging, West Chester, Pa), as previously described. 34 Lung sections were taken from the same position in each set of mice, and at least 4 to 5 random sections per mouse were analyzed. By using digital image capture, tissue regions associated with the entire perivascular/peribroncheal region were viewed, and goblet cells were quantified as the percentage of total mucus-producing cells relative to the total number of airway epithelial cells.
Bronchoalveolar lavage fluid and lung tissue collection for analysis
The trachea was surgically exposed and cannulated with 27-gauge silicon tubing attached to a 23-gauge needle. Bronchoalveolar lavage was performed 3 times with 0.5 mL of PBS per mouse. The bronchoalveolar lavage fluid (BALF) return from individual animals was pooled in plastic tubes on ice and centrifuged (250g) at 48C for 5 minutes. Total cell counts in the BALF were analyzed with a hemocytometer. Thin-layer preparations of BALF were generated by using a Cytospin device and stained with a Diff-Quik stain kit (IMEB, San Marcos, Calif), and differential cell counts were obtained based on the morphology and staining characteristics of at least 200 cells. BALF supernatants were stored at 2808C for cytokine quantification. Murine lung tissue was collected in M-PER protein buffer (Invitrogen, Indianapolis, Ind), homogenized, and then stored at 2808C for future cytokine measurements.
ELISA
Cytokine levels in BALF supernatants and lung homogenates were measured with ELISA kits (IL-4, IL-5, IL-10, IL-13, IL-15, and IFN-g; eBioscience, San Diego, Calif). Detection limits were 4 pg/mL for IL-4, IL-5, IL-13, and IL-15 and 15 pg/mL for IFN-g and IL-10. Eotaxin-1 and eotaxin-2 protein concentrations in the BALF and lung homogenates were quantified by using the DuoSet ELISA Kit (R&D Systems, Minneapolis, Minn). (Fig 3, G) , blood IgE levels (Fig 3, H) , and cytokine and chemokine levels of IL-4, IL-5, IL-13, IFN-g, and eotaxin-1 (Fig 3, I -M) in saline-or Aspergillus species-challenged doxycycline-and non-doxycycline-exposed mice. N-R, Representative photomicrograph of goblet cell hyperplasia (Fig 3, N-Q ) and respective cell numbers in saline-and Aspergillus species-challenged doxycycline-and non-doxycycline-exposed IL-15 bitransgenic mice are shown (Fig 3, R) . Data are expressed as mean 6 SD (n 5 12). *P < .04, **P < .001, and ***P < .0001. A high-resolution version of this slide for use with the Virtual Microscope is available as eSlide: VM03992 (3C, saline-anti-MBP); VM03970 (3E, Aspergillus, anti-MBP); VM03993 (3N, saline challenged PAS stained); VM03971 (3P, Aspergillus, PAS stained showing goblet cell hyperplasia).
Real-time PCR analysis
Total RNA was isolated from lung samples by using TRIZOL (Invitrogen). RNA samples (500 ng) were subjected to reverse transcription analysis by using iScript reverse transcriptase (Bio-Rad Laboratories, Hercules, Calif), according to the manufacturer's instructions. Transcripts of IL-5, IL-4, IL-13, IL-15, eotaxin-1, eotaxin-2, and IL-10 were quantified by using real-time PCR with the IQ5 instrument (Bio-Rad Laboratories). Results were then normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) amplified from the same cDNA mix and expressed as relative expression induction compared with Gapdh. Specific transcripts from cDNA were amplified by using the primers listed in Table I .
Flow cytometric analysis of CD4
1 CD25 1 forkhead box p3-positive regulatory T cells
Our hypothesis was tested with IL-15-inducible lung-specific (rtTA-CC10-IL-15) bitransgenic experimental asthmatic mice. Cells were isolated from the spleens and mediastinal lymph nodes of doxycycline-exposed and non-doxycycline exposed CC10-IL-15 bitransgenic mice in our experimental asthma model. Isolated cells were stained with anti-CD45-fluorescein isothiocyanate, anti-CD4-phycoerythrin (PE), anti-CD25-PE-Cy7, and antiforkhead box p3 (Foxp3)-allophycocyanin (APC) and examined by using flow cytometry. Cells were first stained with anti-CD45-fluorescein isothiocyanate (FITC), anti-CD4-PE, and anti-CD25-PE-Cy7 for cell-surface markers, followed by use of the intracellular Foxp3 Staining Set (eBioscience) with an anti-Foxp3-APC antibody. Intracellular IL-10 in regulatory T cells was analyzed with an IL-10 Staining Set (eBioscience). The samples were analyzed by using the FACSCalibur flow cytometer (BD Biosciences, San Diego, Calif). 38 Signal transducer and activator of transcription 5 (STAT5) activation was examined in purified regulatory T cells. Regulatory T cells were isolated from mouse splenocytes by using the Regulatory T Cell Isolation Kit (Miltenyi Biotec). The isolated regulatory T cells were exposed to 100 ng/mL rIL-15 for 0, 15, 30, 60, or 120 minutes, and STAT5 phosphorylation was examined with a phosphorylated STAT5 antibody (BD Biosciences) by using flow cytometry and Western blot analysis per the protocol described earlier. 39 
Statistical analysis
Data are expressed as mean 6 SD. Statistical significance comparing different groups of mice was determined by using InStat GraphPad Prism 5 software (Version 5.03; GraphPad Software, San Diego, Calif) and the nonparametric 1-way ANOVA Kruskal-Wallis test, followed by Dunn corrections for multiple comparisons. A P value of less than .05 was considered statistically significant.
RESULTS
Endogenous IL-15 deficiency exacerbates airway obstruction and is rescued by pharmacologic delivery of rIL-15 in mice IL-15 polymorphisms and IL-15 deficiency have been reported in asthmatic children. 26 Notably, higher levels of IL-15 were observed in steroid-treated asthmatic patients. 25 Therefore, we tested the hypothesis that endogenous deficiency of IL-15 induces baseline airway resistance and this effect can be rescued by administration of rIL-15 in endogenous IL-15-deficient mice. Baseline airway resistance and compliance in wild-type (WT) and Il15 gene-deficient (Il15 2/2 ) mice were measured by using the Finepoint RC System (Data Sciences International). Our experiments showed that baseline resistance was increased (Fig 1, A) and compliance (Fig 1, B) was decreased in Il15 2/2 mice compared with WT mice. Furthermore, we observed that rescue of Il15 2/2 mice with rIL-15 (10 mg 2 times a week over a period of 3 weeks) decreased airway resistance (Fig 1, A) and increased compliance (Fig 1, B) back to the values measured in WT mice. Saline-treated Il15 2/2 mice demonstrated high resistance that was comparable with that in naive Il15 2/2 mice, whereas WT rIL-15-treated mice did not show any significant change in resistance or compliance.
Furthermore, to establish that IL-15 deficiency indeed exacerbates asthma, we followed a different approach by neutralizing the IL-15 in mice and inducing experimental asthma. The anti-IL-15 neutralization and Aspergillus specieschallenged protocol we used is shown in Fig 1, C. We observed that IL-15-neutralized mice (anti-IL-15, 1 mg/wk over a period of 3 weeks) after allergen challenge exhibit increased resistance (Fig 1, D) and decreased compliance (Fig 1, E) compared with nonneutralized Aspergillus species-challenged mice. Saline-treated IL-15-neutralized mice also showed enhanced baseline resistance and decreased compliance compared with naive nonneutralized mice (Fig 1, D and E) . These data confirm that IL-15 deficiency promotes asthma pathogenesis.
rIL-15 treatment downregulates inflammatory cytokine levels and tissue eosinophilia in experimental asthma

Il15
2/2 mice showed enhanced airway resistance; therefore we assessed whether IL-15 pharmacologic delivery protects mice from the induction of airway obstruction in allergen-challenged asthmatic mice. Accordingly, we pretreated WT mice with saline or rIL-15 and challenged the mice with Aspergillus species extract per the protocol described in Fig E1, A, in this article's Online Repository at www.jacionline.org. Anti-MBP immunostaining detected eosinophils in the lungs of both Aspergillus species-challenged rIL-15-treated and nontreated mice compared with respective control animals (see Fig E1, B-E). Real-time PCR analysis revealed reduced IL-4, IL-5, and IL-13, but not IL-10, mRNA levels in rIL-15-treated mice compared with those in nontreated Aspergillus species-challenged mice (see Fig E1, F-I) , and protein levels of the respective cytokines were also diminished except for levels of IL-10, IgE, and IFN-g (Fig 2, A-F) . However, enumeration of BALF eosinophils indicated reduced numbers in rIL-15-treated mice compared with those in Aspergillus species-challenged mice (Fig 2, G) . Induced PAS-stained goblet cell hyperplasia was observed in Aspergillus species-challenged mice compared with that seen in saline control mice, and there was a notable reduction in numbers of goblet cells in rIL-15-treated Aspergillus species-challenged mice (see Fig  E1, J-M) . Mucus cell-producing goblet cells were counted along the airway epithelium and shown as a percentage of PAS-positive cells (Fig 2, H) .
rIL-15 pretreatment protects mice from AHR and bronchial resistance in the setting of Aspergillus species-induced experimental asthma
We examined AHR and resistance in response to methacholine in Aspergillus species-challenged mice with or without administration of rIL-15. Allergen-challenged mice demonstrated AHR when compared with saline-challenged mice. Methacholine reactivity is presented as the percentage increase in Penh over baseline reactivity in the absence of cholinergic stimuli. Heightened reactivity was seen in response to methacholine in Aspergillus species-challenged mice when compared with that in corresponding saline-challenged mice. Mice treated with rIL-15 and challenged with Aspergillus species showed significantly diminished AHR (Fig 2, I ) and resistance (Fig 2, J) and increased compliance (Fig 2, K) in response to methacholinechallenged compared with sham rIL-15-treated Aspergillus species-challenged mice. Baseline AHR, airway resistance, and compliance in response to methacholine have been shown in rIL-15-treated and saline-challenged mice (Fig 2, I-K) .
Furthermore, to establish that the rIL-15-mediated protection of resistance in response to methacholine is not specific to Aspergillus species, we also examined the response to methacholine in dust mite and cockroach allergen-challenged mice. Here we show that both dust mite and cockroach allergen-challenged mice demonstrated induced methacholine responses to resistance and reduced compliance compared with their respective salinechallenged control animals. However, both the resistance and compliance responses to methacholine in rIL-15-treated dust mite and cockroach allergen-challenged mice were significantly improved compared with saline-treated dust mite or cockroach allergen-challenged mice (see Fig E2, B-E, in this article's Online Repository at www.jacionline.org). These findings indicate that rIL-15 treatment responses are not allergen specific.
Generation of rtTA-CC10-IL-15 bitransgenic mice
Doxycycline-regulated rtTA-CC10-IL-15 bitransgenic mice were generated in our laboratory to further test our hypothesis. Responder transgenic mice (tetO-IL-15 containing germline IL-15 cDNA under the regulation of the tetracycline operator [tetO7]) were generated and bred to the tetracycline reverse transactivator transgenic mouse line CC10-rtTA (expressing rtTA cDNA under the regulation of the lung-specific rat 2.3-kb CC10 promoter) to establish tetracycline-induced rtTA-CC10-IL-15 bitransgenic mice, as shown (Fig 3, A) . rtTA-CC10-IL-15 bitransgenic mice were phenotyped after receiving doxycycline or sham doxycycline food for 3 weeks. The expression of IL-15 mRNA was analyzed by using real-time PCR. The analysis showed an approximately 6-fold increase in expression of Il15 mRNA (Fig 3, B) and protein, similar to earlier reports of lung transgene augmentation in other CC10 promoter-driven bitransgenic mice. 40, 41 In vivo overexpression of IL-15 in these mice will be free from any external endotoxin contamination.
Lung sections and BALF were analyzed for eosinophil accumulation in doxycycline-and non-doxycycline-exposed saline or Aspergillus species-challenged IL-15-overexpressing mice. The anti-MBP immunostaining detected no eosinophils in saline-challenged non-doxycycline-exposed or doxycyclineexposed IL-15-overexpressing mice (Fig 3, C and D) , whereas increased and comparable numbers of tissue eosinophils were detected in both doxycycline-and non-doxycycline-treated Aspergillus species-exposed IL-15-overexpressing mice (Fig  3, E and F) . Of note, induced blood IgE levels and reduced BALF airway eosinophilia in the BALF of doxycyclineexposed Aspergillus species-challenged IL-15 bitransgenic mice were observed compared with the non-doxycyclineexposed Aspergillus species-challenged IL-15 bitransgenic mice (Fig 3, G and H) . Doxycycline-exposed saline-challenged IL-15 bitransgenic mice showed IgE induction compared with non-doxycycline-saline exposed mice, but the IgE level in IL-15 bitransgenic mice was low compared with that in allergen-challenged doxycycline-and non-doxycycline-exposed mice (Fig 3, H) or within the normal range for IgE compared with wild-type mice (Fig 2, E) . mRNA and protein levels of proinflammatory cytokines and chemokines, specifically IL-4, IL-5, IL-13, and eotaxin(s) (see Fig E3, A-E, in this article's Online Repository at www.jacionline.org), were significantly reduced, but the levels of anti-inflammatory cytokines, such as IFN-g, were found to be increased in doxycycline-exposed Aspergillus species-challenged mice compared with the nondoxycycline-exposed Aspergillus species-challenged mice (Fig  3, I-M) . Saline-challenged doxycycline-and non-doxycyclineexposed mice did not exhibit any mucus-producing goblet cells (Fig 3, N and O) ; however, increased numbers of goblet cells were detected in non-doxycycline-exposed Aspergillus species-challenged mice compared with the doxycycline-exposed Aspergillus species-challenged mice (Fig 3, P and Q) . The percentage of PAS-positive cells in the airway epithelium of the Aspergillus species-exposed group among doxycyclineexposed mice was significantly reduced compared with that in the Aspergillus species-challenged non-doxycycline-exposed mice (Fig 3, R) . Doxycycline-regulated IL-15-overexpressing mice show reduced AHR and airway resistance in response to methacholine in the mouse model of Aspergillus species-induced experimental asthma Doxycycline-and non-doxycycline-exposed saline-or Aspergillus species-challenged mice were examined for AHR, airway resistance, and compliance in response to methacholine. Doxycycline-exposed Aspergillus species-challenged mice compared with non-doxycycline-exposed Aspergillus species-challenged mice showed significantly reduced AHR in response to methacholine at the doses of 12.5 and 25 mg/mL methacholine (Fig 4, A) . Similarly, doxycycline-exposed Aspergillus species-challenged IL-15 transgenic mice also showed a significant decrease in resistance (Fig 4, B) and improved compliance (Fig 4, C) compared with non-doxycycline-exposed Aspergillus species-challenged mice in response to methacholine. No significant change was observed in AHR, airway resistance, or compliance in saline-challenged doxycycline-exposed mice and non-doxycycline-exposed mice (Fig 4) .
Regulatory T-cell numbers and IL-10 levels are increased in doxycycline-exposed IL-15-overexpressing mice after experimental asthma induction Regulatory T cells are proposed to play a central role in the maintenance of immunologic tolerance by effectively suppressing induction of inflammatory IgE and T H 2 responses in allergic inflammation. 42 Therefore, we next tested the hypothesis that overexpression of IL-15 can induce regulatory T cells. Accordingly, we enumerated regulatory T cells in the spleens and mediastinal lymph nodes of Aspergillus species-challenged doxycycline-and non-doxycycline-exposed IL-15 transgenic mice. Spleens and mediastinal lymph nodes were harvested, and single-cell suspensions were analyzed for quantification of regulatory T cells by using a flow cytometer in Aspergillus species-challenged mice that were treated with or without doxycycline for 3 weeks before challenge. The cells were stained with anti-CD4-PE, anti-CD25-PE-Cy7, and anti-Foxp3-APC. The CD4 and CD25 expressed cells were first examined with a flow cytometer, and then double-positive CD4
1
CD25
1 expressed cells were gated and analyzed for Foxp3 expression. Foxp3-matched anti-IgG was used as ab isotype match control to correctly identify regulatory T cells. These regulatory T cells are identified as CD4 
Foxp3
1 regulatory T-cell population in the spleen (52.6%) and mediastinal lymph nodes (15.3%) was significantly increased in doxycyclineexposed Aspergillus species-challenged mice compared with non-doxycycline-exposed Aspergillus species-challenged mice (spleens [13.3%] and mediastinal lymph nodes [8.6%] ). Doxycycline-exposed Aspergillus species-challenged mice displayed significantly higher absolute numbers of CD4
1 cells in both spleens and mediastinal lymph nodes (Fig 5, B and C) . Furthermore, to establish that induced regulatory T cells are the source of IL-10, we analyzed IL-10-producing regulatory T cells in the mediastinal lymph nodes of Aspergillus species-challenged non-doxycycline-exposed and 3-weeks doxycycline-exposed IL-15 bitransgenic mice by using intracellular IL-10 cytokine detection kit (eBioscience). The flow cytometric analysis showed that doxycycline-exposed mice induce regulatory T cells and are the source of IL-10 (see Fig  E4, B-E, in this article's Online Repository at www.jacionline. org). However, 5 mg of rIL-10 delivery to the lung (similar to rIL-15) did not improve Aspergillus species-induced airway obstruction in mice and showed comparable airway resistance and compliance with nontreated Aspergillus species-challenged mice (see Fig E5, A and B, in this article's Online Repository at www.jacionline.org). Real-time PCR and ELISA demonstrated significantly higher mRNA and protein levels of IL-10 in the lungs of doxycycline-exposed Aspergillus species-challenged mice compared with those in non-doxycycline-exposed Aspergillus species-challenged mice (Fig 5, D and E) .
Furthermore, our interest was to understand that STAT5 regulates rIL-15-induced regulatory T-cell induction and activation. Therefore, STAT5 activation was examined by means of both flow cytometry and Western blot analysis. Regulatory T cells were isolated from the spleen and exposed to 100 ng/mL rIL-15 for 0, 15, 30, 60, and 120 minutes, and STAT5 phosphorylation was examined by using flow cytometry and Western blot analyses. Both flow cytometry and Western blot analyses showed that rIL-15 activates STAT5 in regulatory T cells within 15 and 30 minutes after exposure (Fig 5, F and G) . These analyses indicate that IL-15-induced regulatory T-cell responses are regulated by STAT5.
Furthermore, to establish that IL-15 deficiency-induced airway obstruction is associated with reduced regulatory T cells, we examined regulatory T cells in saline-and Aspergillus species-challenged anti-IL-15-neutralized and nonneutralized mice. We observed a baseline regulatory T-cell reduction in anti-IL-15-treated mice compared with wild-type mice (35% and 56%) and reduced regulatory T-cell numbers in Aspergillus species-challenged anti-IL-15-treated mice compared with nontreated Aspergillus species-challenged mice (63% to 78%). The data are shown in Fig E6, A-E, in this article's Online Repository at www.jacionline.org. Furthermore, to establish that rescued IL-15 in Il15 2/2 mice increases regulatory T-cell numbers in Il15 2/2 mice, we examined the status of regulatory T cells in rIL-15-treated WT and Il15 2/2 mice. Flow cytometric analysis with anti-CD4-PE, anti-CD25-PE-Cy7, and anti-Foxp3-APC indicated that rIL-15-administered WT and Il15 2/2 mice show increased numbers of regulatory T cells in the spleen compared with nontreated WT and Il15 2/2 mice (see FIG 4 . Analysis of AHR, airway resistance (RI), and compliance (Cydn) in doxycycline-regulated CC10-IL-15-overexpressed mice. AHR (Penh), resistance, and compliance in response to methacholine (MCh) were measured in doxycycline and non-doxycycline diet-fed saline-or Aspergillus species-challenged CC10-IL-15 mice. Data are expressed as mean 6 SD (n 5 10 per group). *P < .05, **P < .01, and ***P < .001. Fig E6, F-J) . These data indicate that IL-15 regulation is critical in asthmatic patients.
IL-15 agonist complex (ALT-803) might be a novel therapeutic agent to reduce airway resistance
Lastly, we examined whether an IL-15 agonist (ALT-803; Altor Biosciences, Miramar, Fla) could serve to reduce allergeninduced airway obstruction. Aspergillus species-challenged mice displayed a significant increase in airway resistance in response to 12.5, 25, and 50 mg/mL methacholine-compared with that seen in saline-challenged mice. ALT-803 pretreatment resulted in a decrease in AHR in Aspergillus species-challenged mice (Fig 6, A and B) . ALT-803 pretreatment also gave rise to a decrease in the number of mucus-producing goblet cells observed in lung sections from Aspergillus species-challenged mice (Fig 6,  C-F) . The quantitation of PAS-positive mucus-producing lung cells demonstrated a highly significant reduction in ALT-803-treated Aspergillus species-challenged mice compared with numbers in Aspergillus species-challenged mice without ALT-803 treatment (Fig 6, G) . Furthermore, we show that ALT-803-treated allergen-challenged mice exhibit significantly higher IL-10 levels compared with allergen-challenged mice that did not receive the compound (Fig 6, H) . However, we observed that ALT-803 treatment did not improve allergen-induced compliance in this experimental model of asthma. This phenomenon can occur on account of the mouse having venous congestion or incomplete filling of alveoli. To help understand this finding, further investigations are needed with different concentrations of ALT-803 in an experimental model of asthma.
DISCUSSION
Airway inflammation manifests as increased numbers of inflammatory cells and higher expression of associated cytokines (Fig 5, B) and mediastinal lymph nodes (Fig 5, C) . D and E, Real-time PCR and ELISA in the lungs of 3 independent experiments of saline-or Aspergillus species-challenged doxycycline-and non-doxycycline-exposed mice for IL-10 mRNA (Fig 5, D) and protein (Fig 5, E) are shown. F and G, In vitro IL-15-induced STAT5 activation in regulatory T cells was analyzed by performing flow cytometry and Western blot analysis. Data are expressed as mean 6 SD. *P < .05.
and chemokines. 43, 44 Allergen-induced airway inflammation (mainly eosinophilic) is associated with an increase in AHR and mucus production. [45] [46] [47] Both the influx of eosinophils and increase in AHR precede development of the late-phase response. 48, 49 In the current study, we demonstrated that reduced levels of IL-15 foster airway obstruction in mice and that rescue with rIL-15 in Il15 2/2 mice mitigates this airway obstruction. Additionally, using a chronic Aspergillus species-induced mouse model of asthma, we provide evidence that overexpression of IL-15 can suppress fundamental features of allergic airway inflammation, as well as airway obstruction. IL-15 is a cytokine implicated in innate and acquired antiviral immunity, and clinical reports implicate an association with pediatric asthma. 25 IL-15 has a critical role in the growth and survival of NK and memory phenotype CD8
1 T cells that sustain innate immunity. 50, 51 IL-15 functions through its specific receptor, IL-15Ra, and also binds to the common cytokine g-chain (CD132) IL-2/IL-15 receptor that shares receptor b (IL-15Rb; CD122). The rationale to investigate IL-15 in asthmatic patients is based on the fact that pediatric asthmatic patients exhibit a relative IL-15 deficiency 26 and because levels of IL-15 are increased after steroid therapy in adult asthmatic patients. 25 Accordingly, we analyzed multiple strategies to test the hypothesis that IL-15 regulation is critical for the induction and protection of airway obstruction in asthmatic mice. Here we used both noninvasive and invasive methods to examine airway function in allergen-induced experimental models. Whole-body plethysmography (Penh), a noninvasive method for measurement of airway responsiveness, has been frequently used in the past, but its validity is now under debate. Therefore to establish that IL-15 overexpression indeed diminishes allergen-induced airway obstruction, we also used an invasive lung resistance measurement. Measurements of airway resistance are considered a more accurate and sensitive procedure for analysis of pulmonary mechanics. 52, 53 Our finding that endogenous IL-15 deficiency enhances airway resistance and reduces lung compliance in the absence of perturbation are consistent with the previously reported clinical findings. 54 Accordingly, we focused our current studies on the protective role of IL-15 on lung inflammation and mechanics in murine asthma models. Our experimental results showed that both pharmacologic lung delivery of rIL-15 and lung-targeted transgenic IL-15 overexpression downregulated the levels of T H 2 cytokines and decreased mucus-producing goblet cell hyperplasia in asthmatic mice. Induction of IL-4, (Fig 6, G) . H, ALT-803-induced IL-10 in BALF of Aspergillus species-challenged mice. Data are expressed as mean 6 SD (n 5 8 mice per group).*P < .01 and **P < .001.
IL-5, and IL-13 is implicated in the pathogenesis of asthma, including the features of inflammation, airway resistance, and diminished compliance. [55] [56] [57] Our studies strongly support the concept that IL-15 protects mice from allergen-induced increase in airway resistance and AHR. Moreover, we demonstrate that this effect is not specific to a particular allergen because the Aspergillus species, dust mite, and cockroach allergen-induced increase in airway resistance and decrease in compliance were improved by rIL-15 treatment for all of these allergens. Mechanistically, we show that the IL-15-induced improvement in airway obstruction might be associated with higher numbers of IL-10-producing CD4
1
CD25
1 regulatory T cells. We discovered that transgeneinduced IL-15 expression results in increased numbers of CD4
1
CD25
1 Foxp3 1 regulatory T cells in mediastinal lymph nodes that circulate and induce the anti-inflammatory cytokine IL-10 in the lungs in an asthma mouse model. Notably, it has been previously documented that IL-10 58,59 or IL-10-producing CD4
1
CD25
1 regulatory T cells can inhibit T H 2-associated airway inflammation. 60, 61 Therefore induction of both regulatory T cells and IL-10 through IL-15 overexpression might be a key mechanism for the observed IL-15-mediated improvement of lung inflammation and airway obstruction. However, our experimentation indicates that direct delivery of IL-10 to the lung is not able to significantly improve airway obstruction induced by allergen in mice. This might be because either the tested dose of IL-10 is not sufficient or because IL-10 requires induction of NK cell-derived IFN-g or other mediators for the protection of airway obstruction. Notably, IL-15 promotes NK cell proliferation and survival. 27, 28 In addition, IL-15 overexpression-induced IgE might also be beneficial and mechanistically contribute to the IL-15-induced protection for airway obstruction. This concept is based on an earlier report that indicates that a small amount of IgE has a significant role in the immune system's recognition that is required for strong cytotoxic responses. 62 Furthermore, we provided clinically relevant supportive data illustrating the effectiveness of an IL-15 agonist (ALT-803) in reducing mucus-producing cell numbers and improving airway resistance in asthmatic mice. These investigations provide a strong preclinical rationale to consider regulation of IL-15 signaling for therapeutic trials in asthmatic patients. IL-15 agonists are currently in phase I clinical trials to evaluate the safety, dosing, and antitumor effects of IL-15 in patients with metastatic melanoma and renal cell carcinoma. 63, 64 ALT-803 is a complex of an IL-15 superagonist mutant and dimeric IL-15 receptor aSu/Fc fusion protein and was found to exhibit significantly stronger in vivo biologic activity than rIL-15. Additionally, dose-response studies indicated that a single dose of ALT-803, as low as 0.05 mg/kg, was capable of reducing 90% of the BM 5T33P myeloma cells in mice. 65 These reports support the usability of ALT-803 in mouse models of asthma. Based on our findings herein, we propose IL-15 immunotherapy might be useful to reduce airway obstruction in patients with asthma.
In conclusion, we first showed that IL-15 deficiency results in increased baseline airway resistance and decreased airway compliance. Second, we report that rIL-15 treatment diminishes allergen-induced airway obstruction in an experimental murine model of asthma. Third, we provide evidence that transgenic IL-15 overexpression in the murine lung is protective against allergen-induced AHR, significantly enhanced levels of IFN-g and IL-10, and reduced levels of proinflammatory cytokines, specifically IL-4, IL-5, and IL-13, as well as goblet cell hyperplasia. Furthermore, we provide mechanistic evidence that the IL-15-regulated reduction in T H 2 cytokine-induced airway inflammation and airway obstruction is associated with higher numbers of IL-10-producing regulatory T cells and induced IFN-g. Taken together, these studies indicate that IL-15 agonists might be a novel approach for nonsteroidal therapy to improve airway obstruction, resistance, and compliance in patients with chronic asthma.
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Clinical implications: Our studies indicate that IL-15 agonists might be a novel nonsteroidal approach to treat asthma, including airway obstruction. 
